This is to inform you that the Board of Directors at their meeting held on 06.02.2026 had inter alia approved the Unaudited Standalone Financial Results for the quarter ended 31.12.2025.
KOVAI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved the unaudited standalone financial results for Q3 FY26 and the nine months ended 31 December 2025. Revenue from operations rose to ₹40,661.98 lakhs, up about 14.6% from ₹35,469.58 lakhs in the year-ago quarter, while 9M FY26 revenue came in at ₹1,17,095.23 lakhs versus ₹1,01,310.12 lakhs last year (~15.6% growth). Profit before tax for Q3 grew to ₹8,713.92 lakhs from ₹7,512.97 lakhs YoY, and standalone profit after tax stood at ₹6,501.99 lakhs versus ₹5,780.37 lakhs (~12.5% growth), taking 9M PAT to ₹18,110.68 lakhs. Basic EPS for Q3 was ₹59.42 (vs ₹52.83) and ₹165.51 for 9M FY26. Auditor VKS Aiyer & Co issued an unqualified review report with no qualifications, and the company confirmed no material impact from the new Labour Codes.
Steady, broad-based growth in revenue and profits across both Healthcare and Education segments with no adverse auditor remarks — broadly positive read for shareholders, though growth rates are healthy rather than exceptional.